The prevalence of persistent prostate cancer after radiotherapy detected at radical cystoprostatectomy for bladder cancer

Joshua J. Meeks, Sean Q. Kern, Guido Dalbagni, James A. Eastham, Jaspreet S. Sandhu*

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose More than half of the men who receive treatment for prostate cancer elect radiotherapy. After radiotherapy recurrence is determined by an increase in prostate specific antigen and not usually by pathological confirmation. We describe the prevalence of persistent gradable prostate cancer in men treated with radiotherapy for prostate cancer at radical cystoprostatectomy for bladder cancer. Materials and Methods A total of 78 patients underwent radiotherapy (brachytherapy and/or external beam radiation) before the development of bladder cancer requiring radical cystectomy at our institution. All tissues were evaluated by a specialized genitourinary pathologist. Results Median time from radiotherapy to radical cystoprostatectomy was 77 months. Gradable prostate cancer was identified in 45% of patients. Of the tumors 69% were Gleason score 7 or greater, 17% were pT3 or greater and 5% showed positive lymph nodes. Men treated more recently were less likely to have gradable prostate cancer, including 100% before 1980, 49% between 1980 and 2000 and 10% from 2000 to the present (p = 0.002) as were those who received external beam radiation alone compared to brachytherapy and combined brachytherapy/external beam radiation (58% vs 27% and 14%, respectively, p = 0.005). Conclusions After radiotherapy 45% of men had persistent prostate cancer (37% of men with no evidence of disease). A decreased prostate cancer rate was associated with later treatment year and combined brachytherapy/external beam radiation regimens. Similar to men treated with radical cystoprostatectomy for muscle invasive bladder cancer, meticulous attention should be paid during prostate removal in men treated with radiotherapy because many may have persistent prostate cancer. In addition, markers other than prostate specific antigen should be studied in men treated with radiotherapy to better identify those with biochemical recurrence.

Original languageEnglish (US)
Pages (from-to)1760-1763
Number of pages4
JournalJournal of Urology
Volume191
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Urinary Bladder Neoplasms
Prostatic Neoplasms
Radiotherapy
Brachytherapy
Radiation
Prostate-Specific Antigen
Recurrence
Neoplasm Grading
Cystectomy
Prostate
Lymph Nodes
Muscles
Therapeutics
Neoplasms

Keywords

  • cystectomy
  • local
  • neoplasm recurrence
  • prostatic neoplasms
  • radiotherapy
  • urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Meeks, Joshua J. ; Kern, Sean Q. ; Dalbagni, Guido ; Eastham, James A. ; Sandhu, Jaspreet S. / The prevalence of persistent prostate cancer after radiotherapy detected at radical cystoprostatectomy for bladder cancer. In: Journal of Urology. 2014 ; Vol. 191, No. 6. pp. 1760-1763.
@article{daea0395f55f4f85a923552f6639bb2a,
title = "The prevalence of persistent prostate cancer after radiotherapy detected at radical cystoprostatectomy for bladder cancer",
abstract = "Purpose More than half of the men who receive treatment for prostate cancer elect radiotherapy. After radiotherapy recurrence is determined by an increase in prostate specific antigen and not usually by pathological confirmation. We describe the prevalence of persistent gradable prostate cancer in men treated with radiotherapy for prostate cancer at radical cystoprostatectomy for bladder cancer. Materials and Methods A total of 78 patients underwent radiotherapy (brachytherapy and/or external beam radiation) before the development of bladder cancer requiring radical cystectomy at our institution. All tissues were evaluated by a specialized genitourinary pathologist. Results Median time from radiotherapy to radical cystoprostatectomy was 77 months. Gradable prostate cancer was identified in 45{\%} of patients. Of the tumors 69{\%} were Gleason score 7 or greater, 17{\%} were pT3 or greater and 5{\%} showed positive lymph nodes. Men treated more recently were less likely to have gradable prostate cancer, including 100{\%} before 1980, 49{\%} between 1980 and 2000 and 10{\%} from 2000 to the present (p = 0.002) as were those who received external beam radiation alone compared to brachytherapy and combined brachytherapy/external beam radiation (58{\%} vs 27{\%} and 14{\%}, respectively, p = 0.005). Conclusions After radiotherapy 45{\%} of men had persistent prostate cancer (37{\%} of men with no evidence of disease). A decreased prostate cancer rate was associated with later treatment year and combined brachytherapy/external beam radiation regimens. Similar to men treated with radical cystoprostatectomy for muscle invasive bladder cancer, meticulous attention should be paid during prostate removal in men treated with radiotherapy because many may have persistent prostate cancer. In addition, markers other than prostate specific antigen should be studied in men treated with radiotherapy to better identify those with biochemical recurrence.",
keywords = "cystectomy, local, neoplasm recurrence, prostatic neoplasms, radiotherapy, urinary bladder neoplasms",
author = "Meeks, {Joshua J.} and Kern, {Sean Q.} and Guido Dalbagni and Eastham, {James A.} and Sandhu, {Jaspreet S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.juro.2013.12.037",
language = "English (US)",
volume = "191",
pages = "1760--1763",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

The prevalence of persistent prostate cancer after radiotherapy detected at radical cystoprostatectomy for bladder cancer. / Meeks, Joshua J.; Kern, Sean Q.; Dalbagni, Guido; Eastham, James A.; Sandhu, Jaspreet S.

In: Journal of Urology, Vol. 191, No. 6, 01.01.2014, p. 1760-1763.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The prevalence of persistent prostate cancer after radiotherapy detected at radical cystoprostatectomy for bladder cancer

AU - Meeks, Joshua J.

AU - Kern, Sean Q.

AU - Dalbagni, Guido

AU - Eastham, James A.

AU - Sandhu, Jaspreet S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose More than half of the men who receive treatment for prostate cancer elect radiotherapy. After radiotherapy recurrence is determined by an increase in prostate specific antigen and not usually by pathological confirmation. We describe the prevalence of persistent gradable prostate cancer in men treated with radiotherapy for prostate cancer at radical cystoprostatectomy for bladder cancer. Materials and Methods A total of 78 patients underwent radiotherapy (brachytherapy and/or external beam radiation) before the development of bladder cancer requiring radical cystectomy at our institution. All tissues were evaluated by a specialized genitourinary pathologist. Results Median time from radiotherapy to radical cystoprostatectomy was 77 months. Gradable prostate cancer was identified in 45% of patients. Of the tumors 69% were Gleason score 7 or greater, 17% were pT3 or greater and 5% showed positive lymph nodes. Men treated more recently were less likely to have gradable prostate cancer, including 100% before 1980, 49% between 1980 and 2000 and 10% from 2000 to the present (p = 0.002) as were those who received external beam radiation alone compared to brachytherapy and combined brachytherapy/external beam radiation (58% vs 27% and 14%, respectively, p = 0.005). Conclusions After radiotherapy 45% of men had persistent prostate cancer (37% of men with no evidence of disease). A decreased prostate cancer rate was associated with later treatment year and combined brachytherapy/external beam radiation regimens. Similar to men treated with radical cystoprostatectomy for muscle invasive bladder cancer, meticulous attention should be paid during prostate removal in men treated with radiotherapy because many may have persistent prostate cancer. In addition, markers other than prostate specific antigen should be studied in men treated with radiotherapy to better identify those with biochemical recurrence.

AB - Purpose More than half of the men who receive treatment for prostate cancer elect radiotherapy. After radiotherapy recurrence is determined by an increase in prostate specific antigen and not usually by pathological confirmation. We describe the prevalence of persistent gradable prostate cancer in men treated with radiotherapy for prostate cancer at radical cystoprostatectomy for bladder cancer. Materials and Methods A total of 78 patients underwent radiotherapy (brachytherapy and/or external beam radiation) before the development of bladder cancer requiring radical cystectomy at our institution. All tissues were evaluated by a specialized genitourinary pathologist. Results Median time from radiotherapy to radical cystoprostatectomy was 77 months. Gradable prostate cancer was identified in 45% of patients. Of the tumors 69% were Gleason score 7 or greater, 17% were pT3 or greater and 5% showed positive lymph nodes. Men treated more recently were less likely to have gradable prostate cancer, including 100% before 1980, 49% between 1980 and 2000 and 10% from 2000 to the present (p = 0.002) as were those who received external beam radiation alone compared to brachytherapy and combined brachytherapy/external beam radiation (58% vs 27% and 14%, respectively, p = 0.005). Conclusions After radiotherapy 45% of men had persistent prostate cancer (37% of men with no evidence of disease). A decreased prostate cancer rate was associated with later treatment year and combined brachytherapy/external beam radiation regimens. Similar to men treated with radical cystoprostatectomy for muscle invasive bladder cancer, meticulous attention should be paid during prostate removal in men treated with radiotherapy because many may have persistent prostate cancer. In addition, markers other than prostate specific antigen should be studied in men treated with radiotherapy to better identify those with biochemical recurrence.

KW - cystectomy

KW - local

KW - neoplasm recurrence

KW - prostatic neoplasms

KW - radiotherapy

KW - urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84900445839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900445839&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2013.12.037

DO - 10.1016/j.juro.2013.12.037

M3 - Article

C2 - 24373801

AN - SCOPUS:84900445839

VL - 191

SP - 1760

EP - 1763

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -